ExpandNew 2026 Hyperlipidemia Guideline Expand Treatment Eligibility from 41% to 55% of Adults
Under the 2026 cholesterol treatment guideline, 54.6% of adults aged 20–79 without established cardiovascular disease were eligible for lipid-lowering therapy, compared with 41.3% under the 2018 guideline, a 13.3 percentage-point increase in the treatment-eligible share.


















